Aptinyx (APTX) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Aptinyx Reports First Quarter 2021 Financial Results and Highlights
May 13, 2021 4:05 PM EDTEnrollment on track in both Phase 2b studies of NYX-2925 in chronic paindata readouts expected 1H 2022
Preparing for NYX-783 Phase 2b PTSD study following recent FDA meetingstudy initiation expected in 2H 2021
Recommenced Phase 2 study of NYX-458 in patients with cognitive impairmentdata readout expected 2H 2022
$146.8 million cash position expected to support operations through multiple Phase 2 readouts and into 2023
Conference call today at 5:00 p.m. ET
EVANSTON, Ill.--(BUSINESS WIRE)-- Aptinyx Inc. (Nasdaq:... More
